Rigel Pharmaceuticals Inc.

RIGL | NASDAQ

Price Alert Chart Builder DCF Calculator

$47.09

+$0.45 (+0.96%)

At close: Sep 21, 2026, 4:00 PM ET

$47.09

$0 (0.00%)

After-hours: Sep 21, 2026, 7:30 PM ET

Overview Rating Statistics Financials Earnings Analysts Ownership Profile

+0.96%

(1D)

Rating

Updated: Aug 13, 2026

78.5

Fundamentals Excellent

Market Sentiment Neutral

Moat Narrow

Full Analysis

Key Statistics

Market Data

Market Cap $871.26M

1D Range

46.50 47.35

52W Range

24.95 52.24

Valuation (TTM)

PE 2.89

PB 2.05

EV/EBITDA 8.76

Valuation (NTM)

Forward PE 8.81

Forward PEG 0.08

Price Target $67

Cash Flow

FCF Yield 9.4%

SBC Adj. FCF Yield 7.1%

SBC Impact -24.2%

Margins

Gross Margin 91.4%

Operating Margin 31.4%

FCF Margin 29.7%

Growth (CAGR)

Revenue 3Y | 5Y 29.8% | 13.9%

Dil EPS 3Y | 5Y 123.0% | 180.9%

FCF 3Y | 5Y 105.1% | 1131.3%

Returns

ROA 61.8%

ROE 96.5%

ROIC 18.7%

Financial Health

Net Cash

$56.09M

Current Ratio 1.95

Interest Coverage 15.00

Dividends

Div Yield N/A

Payout Ratio N/A

FCF Payout Ratio N/A

All Key Statistics

Loading financial charts...

Profile

Rigel Pharmaceuticals, Inc., a biotechnology company, develops and provides therapies that enhance the lives of patients with hematologic disorders and cancer in the United States. The company offers ...

Sector Healthcare

Industry Biotechnology

Employees 173

IPO Date Nov 28, 2000

Website www.rigel.com

Fiscal Year January - December

Full Company Profile

Latest News

No news articles available yet.

Earnings

Next Earnings

Nov 3, 2026

EPS Est

Pro

Rev Est

Pro

Earnings Details ➞

Analyst Summary

# of Analysts

Consensus

Buy

Price Target

$67

Upside

+42.28%

Buy (3)

Hold (2)

Sell (0)

Analyst Details ➞